干旱区生态环境知识资源中心(Arid): A Novel Nomogram for Predicting Morbidity Risk in Patients with Secondary Malignant Neoplasm of Bone and Bone Marrow: An Analysis Based on the Large MIMIC-III Clinical Database

Arid

DOI	10.2147/IJGM.S352761
	A Novel Nomogram for Predicting Morbidity Risk in Patients with Secondary Malignant Neoplasm of Bone and Bone Marrow: An Analysis Based on the Large MIMIC-III Clinical Database
	Miao, Guiqiang; Li, Zhaohui; Chen, Linjian; Li, Wenyong; Lan, Guobo; Chen, Qiyuan; Luo, Zhen; Liu, Ruijia; Zhao, Xiaodong
通讯作者	Zhao, XD
来源期刊	INTERNATIONAL JOURNAL OF GENERAL MEDICINE
EISSN	1178-7074
出版年	2022
卷号	15 页码:3255-3264
英文摘要	Objective: Bone and bone marrow are the third most frequent sites of metastases from many cancers and are associated with low survival and high morbidity rates. Currently, there are no effective bedside tools to predict the morbidity risk of these patients in general intensive care units (ICUs). The main objective of this study was to establish and validate a nomogram to predict the morbidity risk of patients with bone and bone marrow metastases. Methods: Data on patients with bone and bone marrow metastases were extracted from the Medical Information Mart for Intensive Care III (MIMIC-III) database. The patients were divided into training and validation cohorts. The data were analyzed using univariate and multivariate Cox regression methods. Factors significantly and independently prognostic of survival were used to construct a nomogram predicting 30-day morbidity. The nomogram was validated by various methods, including Harrell's concordance index (C-index), area under the receiver operating characteristic curve (AUC), calibration curve, integrated discrimination improvement (IDI), net reclassification index (NRI), and decision curve analysis (DCA). Results: The study included 610 patients in the training cohort and 262 in the validation cohort. Multivariate Cox regression analysis showed that temperature, SpO(2), Sequential Organ Failure Assessment (SOFA) score, Oxford Acute Severity of Illness Score (OASIS), comorbidities with coagulopathy, white blood cell count, heart rate, and respiratory rate were independent predictors of patient survival. The resulting nomogram had good discriminative ability, as shown by high AUCs, and was well calibrated, as demonstrated by calibration curves. Improvements in NRI and IDI values suggested that the nomogram was superior to the SOFA scoring system. DCA curves revealed that the nomogram showed good value in clinical applications. Conclusion: This prognostic nomogram, based on demographic and laboratory parameters, was predictive of the 30-day morbidity rate in patients with secondary malignant neoplasms of the bone and bone marrow, suggesting its applicability in clinical practice.
英文关键词	secondary malignant neoplasm of bone and bone barrow MIMIC-III database prognosis nomogram
类型	Article
语种	英语
开放获取类型	Green Published, gold
收录类别	SCI-E
WOS记录号	WOS:000775985200003
WOS关键词	INTENSIVE-CARE-UNIT ; PROGNOSTIC-FACTORS ; CANCER ; PATHOPHYSIOLOGY ; TRANSPLANTATION ; TEMPERATURE ; SURVIVAL ; OUTCOMES ; DISEASE ; SEPSIS
WOS类目	Medicine, General & Internal
WOS研究方向	General & Internal Medicine
资源类型	期刊论文
条目标识符	http://119.78.100.177/qdio/handle/2XILL650/393188
推荐引用方式 GB/T 7714	Miao, Guiqiang,Li, Zhaohui,Chen, Linjian,et al. A Novel Nomogram for Predicting Morbidity Risk in Patients with Secondary Malignant Neoplasm of Bone and Bone Marrow: An Analysis Based on the Large MIMIC-III Clinical Database[J],2022,15:3255-3264.
APA	Miao, Guiqiang.,Li, Zhaohui.,Chen, Linjian.,Li, Wenyong.,Lan, Guobo.,...&Zhao, Xiaodong.(2022).A Novel Nomogram for Predicting Morbidity Risk in Patients with Secondary Malignant Neoplasm of Bone and Bone Marrow: An Analysis Based on the Large MIMIC-III Clinical Database.INTERNATIONAL JOURNAL OF GENERAL MEDICINE,15,3255-3264.
MLA	Miao, Guiqiang,et al."A Novel Nomogram for Predicting Morbidity Risk in Patients with Secondary Malignant Neoplasm of Bone and Bone Marrow: An Analysis Based on the Large MIMIC-III Clinical Database".INTERNATIONAL JOURNAL OF GENERAL MEDICINE 15(2022):3255-3264.